Nivolumab Gets FDA Nod for Classical Hodgkin Lymphoma in 2025 Drug Approval Wave
MSK-led research drove 10 FDA cancer drug approvals in 2025, including nivolumab combined with chemotherapy for classical Hodgkin lymphoma.
Summary
Memorial Sloan Kettering Cancer Center announced that its researchers contributed to 10 new FDA cancer drug approvals in 2025, highlighting the institution's outsized role in translating laboratory science into approved therapies. Among the most notable recent approvals is nivolumab (Opdivo) in combination with doxorubicin, vinblastine, and dacarbazine for classical Hodgkin lymphoma, approved March 20, 2026. Nivolumab is a checkpoint inhibitor that blocks the PD-1 pathway, freeing the immune system to attack cancer cells. Adding it to a standard chemotherapy backbone represents a meaningful advance for Hodgkin lymphoma patients, a disease that predominantly affects younger adults. The breadth of MSK's 2025 approval portfolio reflects growing momentum in immunotherapy, targeted therapy, and precision oncology — areas directly relevant to improving cancer survival and quality of life.
Detailed Summary
Memorial Sloan Kettering Cancer Center reported that MSK-led research contributed to 10 new FDA cancer drug approvals across 2025, underscoring the institution's central role in moving experimental therapies from bench to bedside. For oncologists and longevity-focused clinicians, each approval represents a narrowing gap between diagnosis and effective, evidence-based treatment.
The most clearly documented recent approval is nivolumab (Opdivo) in combination with doxorubicin, vinblastine, and dacarbazine — a regimen now approved for classical Hodgkin lymphoma as of March 20, 2026. Nivolumab is a PD-1 checkpoint inhibitor that has already transformed treatment in melanoma, lung cancer, and renal cell carcinoma. Its addition to this established chemotherapy backbone extends the immunotherapy revolution into Hodgkin lymphoma, a cancer most common in people aged 15–35 and adults over 55.
Classical Hodgkin lymphoma is already highly treatable, but a subset of patients experience relapse or are refractory to initial therapy. Combining checkpoint blockade with frontline chemotherapy aims to deepen initial responses, potentially reducing the need for aggressive salvage regimens or stem cell transplantation. Early data supporting this combination suggest improved progression-free survival, though long-term durability data are still maturing.
The broader MSK announcement, citing 10 total approvals in 2025, points to a remarkably productive year for academic-industry collaboration in oncology. Drug classes likely represented include antibody-drug conjugates, bispecific antibodies, targeted small molecules, and additional immunotherapies — reflecting the diversification of the cancer treatment arsenal.
For longevity medicine practitioners, these approvals matter because cancer remains a leading cause of mortality across all age groups, and effective early-line therapies directly improve both lifespan and healthspan. Caveats include incomplete data on the full list of 2025 approvals from this source, and the long-term safety profile of nivolumab combinations warrants ongoing monitoring for immune-related adverse events.
Key Findings
- Nivolumab combined with doxorubicin, vinblastine, and dacarbazine received FDA approval for classical Hodgkin lymphoma on March 20, 2026.
- MSK-led research contributed to 10 FDA cancer drug approvals in 2025, signaling exceptional translational research output.
- Adding PD-1 checkpoint inhibition to frontline Hodgkin lymphoma chemotherapy aims to deepen remissions and reduce relapse rates.
- The approval expands nivolumab's label into a cancer predominantly affecting younger adults and older adults over 55.
- Immune-related adverse events remain a key monitoring consideration for all nivolumab-containing regimens.
Methodology
This content is derived from an institutional press release by MSK and FDA approval notification records, not a primary clinical trial publication. The nivolumab approval was identified from FDA oncology announcement records dated March 20, 2026. Full trial methodology underlying the approval was not available in the source material reviewed.
Study Limitations
This summary is based on an institutional press release and limited FDA announcement data, not a peer-reviewed clinical trial publication. The complete list of 10 MSK-associated 2025 approvals was not available in the source material, limiting comprehensive analysis. Long-term efficacy and safety data for the nivolumab plus chemotherapy combination in Hodgkin lymphoma are still maturing.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.